Marketing
-
Takeda wins FDA approval for targeted lung cancer drug
Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene. Unlike J&J's drug, however, Takeda's is given orally.
By Kristin Jensen • Sept. 16, 2021 -
Permission granted by University of Maryland School of Medicine
New data from Israel, Pfizer show potent effect from third coronavirus shot
The much-anticipated data arrive ahead of an important FDA advisory meeting to discuss authorization of a booster dose for Pfizer's coronavirus vaccine.
By Jonathan Gardner • Sept. 15, 2021 -
Permission granted by IQVIA
Sponsored by IQVIAOvercoming inertia: Adopting omnichannel marketing for pharma
Pharmaceutical companies are increasingly attracted to the idea of replacing the current multichannel marketing focus with an omnichannel marketing approach. But the industry is struggling to break out of its own silos.
By Andrew Burkus, Principal, Omnichannel Marketing, IQVIA • Sept. 13, 2021 -
Permission granted by Biogen
Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.
At Morgan Stanley’s healthcare conference last week, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage.
By Jacob Bell • Sept. 09, 2021 -
Sean Gallup via Getty Images
Settling lawsuit, AstraZeneca and European Commission agree on coronavirus vaccine delivery
The U.K.-based drugmaker fell behind on its promise to supply 300 million doses by the end of June to countries in the trading bloc. Now, it's set to reach that target by March 2022.
By Jonathan Gardner • Sept. 03, 2021 -
Sarah Silbiger via Getty Images
With safety worries mounting, FDA limits who can take certain immune-regulating drugs
The agency has new rules for who can take Pfizer's Xeljanz, Eli Lilly's Olumiant or AbbVie's Rinvoq after a large study raised concerns about the safety of so-called JAK inhibitors.
By Jacob Bell • Sept. 01, 2021 -
Elizabeth Regan / Industry Dive
BioMarin wins European approval to sell drug for dwarfism
The drugmaker is setting the price for Voxzogo high, at an annual price of around $300,000 per patient, although the company expects to make "material discounts" in the coming years.
By Ned Pagliarulo • Aug. 27, 2021 -
Permission granted by UPS
UPS delivers coronavirus vaccines via temperature-controlled drone
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas.
By Matt Leonard • Aug. 25, 2021 -
Lilly, preparing Alzheimer's drug plans, forms new neuroscience unit in company restructure
Lilly Bio-Medicines will be split into separate neuroscience and immunology groups, while the Loxo cancer research division will merge with Lilly Oncology.
By Jonathan Gardner • Aug. 17, 2021 -
Bluebird to wind down business in Europe amid gene therapy struggles
Shares in the biotech sunk in value as the company also announced new safety concerns for one of its leading programs.
By Jacob Bell • Aug. 09, 2021 -
SDI Productions via Getty Images
Sponsored by FedEx Office5 lessons about the importance of print in biopharma in a post-pandemic world
Biopharma businesses have started to reevaluate relationships with print suppliers to determine what's working and what's not.
-
Permission granted by Biogen
After controversial approval, doctors are still debating how to use Biogen's Alzheimer's drug
Nearly two months since Aduhelm became available, many physicians have yet to use the first treatment approved in the U.S. to slow Alzheimer's disease.
By Jacob Bell • UPDATED: Aug. 3, 2021 at 3:59 p.m. -
Permission granted by Health Union
Sponsored by Health UnionSocial health: The future of healthcare marketing
Approximately 79% of patients look to connect through social media to find answers to their health questions.
-
Permission granted by Biogen
Major health centers, insurers push back against Aduhelm
The Cleveland Clinic and Mount Sinai won't yet administer the controversial Alzheimer's drug, while UnitedHealth's CEO said the insurer would need more time to iron out coverage.
By Jacob Bell • July 15, 2021 -
Permission granted by Biohaven Pharmaceutical
Q&ABiohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma
Sales of Nurtec ODT during the second quarter were double what Wall Street expected. CEO Vlad Coric explained to BioPharma Dive how the biotech did it, despite being far smaller than its chief rival.
By Jacob Bell • July 14, 2021 -
Permission granted by Biogen
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
CMS will consider whether to set a single policy for Aduhelm, a process that could shape how millions of Americans access the controversial treatment.
By Ned Pagliarulo • UPDATED: July 13, 2021 at 11:15 a.m. -
Permission granted by Biogen
Alzheimer's Association, insurers press Medicare for coverage rules on Aduhelm
Days after the FDA narrowed the target population for Biogen's drug, the patient advocacy group said it's urging Medicare to adopt a nationwide policy. Payers are seeking guidance, too.
By Jonathan Gardner • UPDATED: July 12, 2021 at 5:20 p.m. -
Getty / Edited by BioPharma Dive
Bluebird resumes marketing gene therapy in Europe
Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.
By Jacob Bell • July 09, 2021 -
Getty Images
Biohaven beats expectations with fast sales of migraine drug
Second quarter sales of Nurtec ODT, which recently became the first migraine drug cleared for acute and preventive treatment, were nearly twice what analysts on Wall Street had predicted.
By Ned Pagliarulo • July 08, 2021 -
Permission granted by Biogen
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
Aduhelm's approval last month, already highly controversial, was made more so by the agency's decision to clear the drug for a broad group of patients. New prescribing information more closely matches clinical testing criteria.
By Ned Pagliarulo , Ben Fidler • July 08, 2021 -
Sean Gallup via Getty Images
WHO backs Roche, Sanofi drugs for COVID-19 after research ups and downs
Once long-shot experiments in the rush to repurpose drugs for COVID-19, both Actemra and Kevzara could become more widely used, renewing questions around cost and access.
By Ben Fidler • July 07, 2021 -
Nestlé joins Seres in deal to market microbiome drug
The health science unit at Nestlé may pay more than $500 million to secure rights in the U.S. and Canada for SER-109, a spore-filled capsule meant for patients with recurrent C. diff infections.
By Kristin Jensen • July 01, 2021 -
Permission granted by Biogen
ICER stands by view on Biogen's Aduhelm, says sharp price cut needed
The influential nonprofit maintains that the clinical trial evidence supporting Aduhelm is insufficient to prove a health benefit. But if some efficacy is assumed, ICER argues Biogen's $56,000 price tag is far too high.
By Ned Pagliarulo • June 30, 2021 -
SDI Productions via Getty Images
Sponsored by FedEx OfficeHow biopharma innovation may benefit from more inclusive print communications
Medical advancements are evolving at a rapid pace, and so is public consumption of information.
-
European regulators push 8 drugs toward approval, including controversial anemia pill
A key committee of the EMA gave a positive review of Astellas and Fibrogen's roxadustat, as well as Bristol Myers Squibb's cell therapy Abecma and UCB's psoriasis drug Bimzelx.
By Jacob Bell • June 25, 2021
